Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin in Advanced Alcoholic Liver Fibrosis
NCT04971577Phase 3Recruiting
- Start
- Feb 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of simvastatin in Liver Fibrosis (LF) and alcoholic liver disease (ALD) (2 arms). Primary endpoint: Change from baseline biopsy in histological fibrosis Ishak score at 18 months. Started Feb 2022; status: recruiting.
02
Drugs
simvastatin
03
Conditions
Liver Fibrosis (LF)alcoholic liver disease (ALD)
Beyond the preview
Go deeper on NCT04971577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971577.